Schein's nortriptyline
Executive Summary
Generic marketer more than doubles its 1993 target sales for antidepressant. Budgeted target was about $37 mil.; Schein sales reached $88 mil. Schein began marketing nortriptyline in mid-1992 before patent expiration of the branded Pamelor under an exclusive license from Sandoz. The generic nortriptyline sales may be further evidence of the broad increase in the use of antidepressants from the recent publicity on the serotonin reuptake inhibitors